ENTA Enanta Pharmaceuticals (ENTA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001177648
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
61
13F, latest reported quarter
Enanta Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for ENANTA PHARMACEUTICALS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 2, 2025.
- The trade is 3.9% of the 8,377 shares held after it.
- 6 other insiders sold within 30 days.
- 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Capps Kathleen S. sold about $4.6K of ENTA on Dec 5, 2025; 6 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 2, 2025.
- The trade is 3.3% of the 16,348 shares held after it.
- 6 other insiders sold within 30 days.
- 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Trout Harry R. III sold about $7.7K of ENTA on Dec 5, 2025; 6 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Dec 6, 2024.
- The trade is 3.7% of the 21,792 shares held after it.
- 6 other insiders sold within 30 days.
- 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Rottinghaus Scott T. sold about $11.4K of ENTA on Dec 5, 2025; 6 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 6, 2024.
- The trade is 3.6% of the 38,329 shares held after it.
- 6 other insiders sold within 30 days.
- 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Luu Brendan sold about $19.8K of ENTA on Dec 5, 2025; 6 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Dec 6, 2024.
- The trade is 6.9% of the 30,620 shares held after it.
- 6 other insiders sold within 30 days.
- 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Product Strategy Officer Kieffer Tara Lynn sold about $30.0K of ENTA on Dec 5, 2025; 6 other insiders sold within 30 days and 61 funds added in the latest 13F quarter.67 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
61 funds bought in last quarter
more than 52% of Pharma & Biotech
Revenue
-3.4% year over year
below 61% of Pharma & Biotech
Margin
-125.4% net margin
below 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.3% of the float short (float per yahoo 2026-10-26) · 9.2 days to cover · settled 2026-09-30
more than 67% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ENTA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+11.0%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ENTA: institutional holders (13F)
13F holdings, latest reported quarter
3,654,920 sh
$53.3M
3,244,448 sh
$47.3M
2,418,202 sh
$35.3M
1,444,167 sh
$21.1M
1,344,510 sh
$19.6M
Congress trades in ENTA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ENTA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ENTA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$70.7K position · as of 2026-05-31
0.4%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.4M position · as of 2026-05-31
0.3%
Ultra-Small Company Market Fund
$255.2K position · as of 2026-06-30
0.2%
Schwab Small-Cap Equity Fund
$966.6K position · as of 2026-07-31
0.1%
GMO U.S. Small Cap Value Fund
$65.0K position · as of 2026-05-31
0.1%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND
$4.1M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
15 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
7
Phase 1
1 active
8
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.8M
$3.6M
$1.3M
-77%
n/a
2024
$2.7M
$2.2M
$1.3M
-80%
n/a
2023
$7.9M
-$2.5M
$2.8M
-78%
n/a
2022
$7.3M
$5.4M
$2.9M
+13%
-11%
2021
$5.3M
$6.3M
$2.1M
+24%
+19%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 61 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ENTA financials
Revenue growth
-3.4%
XBRL, annual
Net margin
-125.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$65.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ENTA
| FY Sep 2025 | $65.3M |
| FY Sep 2024 | $67.6M |
| FY Sep 2023 | $79.2M |
| FY Sep 2022 | $86.2M |
| FY Sep 2021 | $97.1M |
| Jun 2026 | $14.4M |
| Mar 2026 | $17.2M |
| Dec 2025 | $18.6M |
| Sep 2025 | $15.1M |
| Jun 2025 | $18.3M |
| Mar 2025 | $14.9M |
| Dec 2024 | $17.0M |
| Sep 2024 | $14.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-96.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ENTA
| FY Sep 2025 | -125.4% |
| FY Sep 2024 | -171.6% |
| FY Sep 2023 | -169.0% |
| FY Sep 2022 | -141.3% |
| FY Sep 2021 | -81.4% |
| Jun 2026 | -135.8% |
| Mar 2026 | -76.3% |
| Dec 2025 | -64.1% |
| Sep 2025 | -123.6% |
| Jun 2025 | -99.7% |
| Mar 2025 | -151.7% |
| Dec 2024 | -131.4% |
| Sep 2024 | -197.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$36.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ENTA
| FY Sep 2025 | -$32.2M |
| FY Sep 2024 | -$96.7M |
| FY Sep 2023 | -$112.2M |
| FY Sep 2022 | -$86.9M |
| FY Sep 2021 | -$70.7M |
| Jun 2026 | -$10.0M |
| Mar 2026 | -$7.2M |
| Dec 2025 | -$11.8M |
| Sep 2025 | -$7.9M |
| Jun 2025 | $17.4M |
| Mar 2025 | -$16.0M |
| Dec 2024 | -$25.5M |
| Sep 2024 | -$19.4M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity ENTA
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt ENTA
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-70.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ENTA
| FY Sep 2025 | -84.6% |
| FY Sep 2024 | -67.2% |
| FY Sep 2023 | -49.7% |
| FY Sep 2022 | -33.8% |
| FY Sep 2021 | -18.5% |
| Jun 2026 | -70.1% |
| Mar 2026 | -59.0% |
| Dec 2025 | -60.0% |
| Sep 2025 | -84.6% |
| Jun 2025 | -80.6% |
| Mar 2025 | -74.3% |
| Dec 2024 | -69.1% |
| Sep 2024 | -67.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-21.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ENTA
| FY Sep 2025 | -24.9% |
| FY Sep 2024 | -27.7% |
| FY Sep 2023 | -31.9% |
| FY Sep 2022 | -29.9% |
| FY Sep 2021 | -17.1% |
| Jun 2026 | -21.2% |
| Mar 2026 | -19.4% |
| Dec 2025 | -21.1% |
| Sep 2025 | -24.9% |
| Jun 2025 | -26.3% |
| Mar 2025 | -26.2% |
| Dec 2024 | -27.0% |
| Sep 2024 | -27.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ENTA
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-23.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ENTA
| FY Sep 2025 | -31.0% |
| FY Sep 2024 | -33.9% |
| FY Sep 2023 | -36.8% |
| FY Sep 2022 | -33.1% |
| FY Sep 2021 | -25.3% |
| Jun 2026 | -23.5% |
| Mar 2026 | -22.1% |
| Dec 2025 | -25.0% |
| Sep 2025 | -31.0% |
| Jun 2025 | -32.4% |
| Mar 2025 | -32.1% |
| Dec 2024 | -33.2% |
| Sep 2024 | -33.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ENTA
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value ENTA
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-10.9%
TTM free cash flow over market value at close 2026-10-23
FCF yield ENTA
| FY Sep 2025 | -12.6% |
| FY Sep 2024 | -44.1% |
| FY Sep 2023 | -47.7% |
| FY Sep 2022 | -8.1% |
| FY Sep 2021 | -6.2% |
| Jun 2026 | -8.7% |
| Mar 2026 | -2.6% |
| Dec 2025 | -4.1% |
| Sep 2025 | -12.6% |
| Jun 2025 | -27.0% |
| Mar 2025 | -69.8% |
| Dec 2024 | -79.2% |
| Sep 2024 | -44.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ENTA
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M |
| Operating income | -$85.3M | -$121.7M | -$137.2M | -$123.8M |
| Net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M |
| EPS (diluted) | -3.84 | -5.48 | -6.38 | -5.91 |
| Operating cash flow | -$19.3M | -$78.8M | -$103.2M | -$84.8M |
| Cash | $32.3M | $37.2M | $85.4M | $44.0M |
SEC XBRL, fiscal years, as known on 2026-10-27
ENTA Stock Sonar score 4/7 axes
Find similar shapesCompareENTA ranks highest on risk and compliance (66th percentile) and profitability (60th), and lowest on growth (39th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
